Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy
Castro D, Prajapati S, Feng M, Chan E, Lee K, Paul T, Sehgal I, Patel J, Li X, Zengin Z, Ebrahimi H, Govindarajan A, Meza L, Mercier B, Chawla N, Dizman N, Philip E, Hsu J, Bergerot C, Chehrazi‐Raffle A, Rock A, Liu S, Tripathi A, Dorff T, Pal S. Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy. BJU International 2023, 133: 297-304. PMID: 37548533, DOI: 10.1111/bju.16148.Peer-Reviewed Original ResearchHBV/HCV infectionExclusion of patientsHepatitis B virusConcurrent malignancyBrain metastasesEligibility criteriaHCV infectionSystemic therapyRCC trialsVirus infectionExact testHepatitis C virus infectionHuman immunodeficiency virus (HIV) infectionC virus infectionImmunodeficiency virus infectionFisher's exact testRestrictive eligibility criteriaContext of HIVChi-square testPrevalent comorbiditiesHIV infectionImmunotherapy trialsPatient populationB virusTrial characteristicsExamining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer Research
Ebrahimi H, Castro D, Feng M, Prajapati S, Lee K, Chan E, Paul T, Sehgal I, Patel J, Li X, Zengin Z, Meza L, Mercier B, Hsu J, Govindarajan A, Chawla N, Dizman N, Bergerot C, Rock A, Liu S, Tripathi A, Dorff T, Pal S, Chehrazi-Raffle A. Examining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer Research. Clinical Genitourinary Cancer 2023, 21: e467-e473. PMID: 37301665, DOI: 10.1016/j.clgc.2023.05.013.Peer-Reviewed Original ResearchConceptsProstate cancer clinical trialsHBV/HCV infectionCancer clinical trialsHepatitis B virusClinical trialsConcurrent malignancyBrain metastasesEligibility criteriaHCV infectionHIV infectionExclusion criteriaClinical OncologyEastern Cooperative Oncology Group scaleAssessment of recommendationsECOG PS 0C virus infectionRestrictive eligibility criteriaAmerican SocietyCancer researchHCV positivityPS 0HIV positivityImmunotherapy trialsB virusVirus infection